Integra Lifesciences Holdings (IART) Net Cash Flow Growth (3y) (2012 - 2026)
Integra Lifesciences Holdings (IART) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.81 Bn | 99.59 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.39 Bn | 66.94 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.28 Bn | 44.60 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.30 Bn | 26.01 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -48.90% |
| 10 | Integra Lifesciences Holdings | 1.51 Bn | 1.25 Bn | 216.98 Mn | 26.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.45% |
| Dec 31, 2025 | 26.38% |
| Sep 30, 2025 | -41.55% |
| Jun 30, 2025 | -39.14% |
| Mar 31, 2025 | 51.46% |
| Dec 31, 2024 | -2.40% |
| Sep 30, 2024 | -28.12% |
| Jun 30, 2024 | -198.63% |
| Mar 31, 2024 | 101.84% |
| Dec 31, 2023 | -27.69% |
| Sep 30, 2023 | -44.61% |
| Jun 30, 2023 | 49.09% |
| Mar 31, 2023 | -43.11% |
| Dec 31, 2022 | -71.08% |
| Sep 30, 2022 | 27.49% |
| Jun 30, 2022 | 39.68% |
| Mar 31, 2022 | -94.96% |
| Dec 31, 2021 | 38.11% |
| Sep 30, 2021 | 48.83% |
| Jun 30, 2021 | -130.00% |